Trial Profile
Relative Bioavailability Study of Three Different Tablet Formulations of GSK1349572 50 mg and the Dose Proportionality of and Effect of Food on the Selected Formulation in Healthy Male and Female Volunteers (ING113674).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; Shionogi ViiV Healthcare LLC
- 12 Oct 2021 Results assessing Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children from 5 pharmacokinetic studies published in the Pediatric Infectious Disease Journal
- 19 Dec 2011 Results published in Antimicrobial Agents and Chemotherapy.
- 16 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.